Camac Fund Ups Stake in Forte Biosciences

Ticker: FBRX · Form: SC 13D/A · Filed: Jun 17, 2024 · CIK: 1419041

Sentiment: neutral

Topics: ownership-change, sec-filing, schedule-13d

Related Tickers: FBRX

TL;DR

Camac Fund just filed an amendment to their 13D on Forte Biosciences. Big ownership change.

AI Summary

Camac Fund, LP, through its filing on June 17, 2024, has amended its Schedule 13D regarding Forte Biosciences, Inc. The filing indicates a change in beneficial ownership, with Camac Fund, LP now holding a significant stake in the company's common stock. The specific percentage and number of shares are detailed within the filing.

Why It Matters

This filing signals a notable shift in the ownership structure of Forte Biosciences, potentially influencing future strategic decisions and stock performance.

Risk Assessment

Risk Level: medium — Changes in beneficial ownership filings can indicate activist investor interest or a shift in control, which may lead to increased volatility.

Key Numbers

Key Players & Entities

FAQ

What is the specific percentage of Forte Biosciences' common stock now beneficially owned by Camac Fund, LP?

The filing does not explicitly state the exact percentage of ownership in the provided text, but it is an amendment to a Schedule 13D, indicating a change in beneficial ownership.

What was the previous ownership percentage of Camac Fund, LP in Forte Biosciences?

The provided text does not specify the previous ownership percentage.

What is the CUSIP number for Forte Biosciences, Inc. common stock?

The CUSIP number for Forte Biosciences, Inc. common stock is 34962G109.

Who is listed as a contact person for Camac Partners, LLC?

Eric Shahinian is listed as a contact person for Camac Partners, LLC.

What is the business address of Forte Biosciences, Inc.?

The business address of Forte Biosciences, Inc. is 3060 Pegasus Park Drive, Building 6, Dallas, TX 75247.

Filing Stats: 4,302 words · 17 min read · ~14 pages · Grade level 14 · Accepted 2024-06-17 06:24:36

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete, and correct. Dated: June 17, 2024 CAMAC FUND, LP By: Camac Capital, LLC its General Partner By: /s/ Eric Shahinian Name: Eric Shahinian Title: Manager CAMAC PARTNERS, LLC By: Camac Capital, LLC its Managing Member By: /s/ Eric Shahinian Name: Eric Shahinian Title: Manager CAMAC CAPITAL, LLC By: /s/ Eric Shahinian Name: Eric Shahinian Title: Manager /s/ Eric Shahinian Eric Shahinian Individually and as attorney-in-fact for Michael G. Hacke ATG FUND II LLC By: ATG Capital Management, LLC Managing Member By: /s/ Gabriel Gliksberg Name: Gabriel Gliksberg Title: Managing Member ATG CAPITAL MANAGEMENT, LLC By: /s/ Gabriel Gliksberg Name: Gabriel Gliksberg Title: Managing Member /s/ GABRIEL GLIKSBERG GABRIEL GLIKSBERG 19 MCINTYRE PARTNERSHIPS, LP By: McIntyre Capital GP, LLC its General Partner By: /s/ Chris McIntyre Name: Chris McIntyre Title: Managing Member MCINTYRE CAPITAL GP, LLC By: /s/ Chris McIntyre Name: Chris McIntyre Title: Managing Member MCINTYRE CAPITAL MANAGEMENT, LP By: McIntyre Capital Management GP, LLC its General Partner By: /s/ Chris McIntyre Name: Chris McIntyre Title: Managing Member MCINTYRE CAPITAL MANAGEMENT GP, LLC By: /s/ Chris McIntyre Name: Chris McIntyre Title: Managing Member /s/ Chris McIntyre Chris McIntyre 20

View Full Filing

View this SC 13D/A filing on SEC EDGAR

View on Read The Filing